MedPath

Closed-blood Sampling Devices in the Adult Critically Ill Patient

Not Applicable
Not yet recruiting
Conditions
Acceptability of Health Care
Interventions
Device: Closed-Blood Sampling Devices
Other: Waste discard volume
Registration Number
NCT06478160
Lead Sponsor
University of Barcelona
Brief Summary

Based on the hypothesis that the strategy of using Closed-Blood Sampling Devices (CSBD, experimental group) compared to the usual practice (waste discard volume, control group), in critically ill adult patients, will decrease the amount of blood withdrawn for laboratory tests, we want to analyze the number of red blood cells (RBC) administered and arterial catheter-related adverse events (catheter-related bacteremia, catheter obstruction, CBSD malfunction, loss of arterial pressure waveform on the patient's bedside monitor) in both study groups, during ICU stay and up to a maximum of 21 days.

Detailed Description

When a patient with an arterial catheter completes 24h of admission to the unit, with an expected catheter stay of more than 72 hours, inclusion in the study will be assessed. If the patient does not meet the non-inclusion or exclusion criteria and consents to participate in the study, he/she will be randomized to the CBSD-experimental group or waste discard volume- control group.

If the patient belongs to the CBSD-experimental group, the CBSD will be placed in the arterial line at that moment. All extractions performed will be through the arterial catheter and using the CBSD.

In the waste discard volume- control group, the arterial catheter will also be used for extractions but with the usual open extraction system of the ICU. To quantify the blood loss related to blood collection for laboratory tests, the volume of discharge (VD) used for each analysis through the arterial catheter will be recorded. In the CBSD-experimental group the VD for arterial catheter will be zero since CBSD will always be used. The laboratory tubes extracted in each analysis will also be recorded.

Data on blood analysis, blood transfusion and adverse events related to the arterial catheter will be recorded daily during the ICU stay, up to day 21 maximum and/or day of ICU discharge and/or exitus.

Patients discharged from ICU to hospitalization will be followed only during the first 48h to know if they have received red blood cell concentrates and with what previous Hemoglobine (Hb) and hematocrit (Hto).

Catheter insertion and maintenance will be carried out in the same way in both groups.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
216
Inclusion Criteria
  • Adult patients with an arterial catheter who agree to participate in the study, with a stay in the ICU of 24h and a minimum of 72h more with an arterial catheter

Non-inclusion criteria: Therapeutic Limitation of Life Support, Jehovah's Witnesses.

Exclusion Criteria
  • Patients with chronic renal failure
  • Patients with active gastrointestinal bleeding
  • Patients diagnosed with hematologic cancer
  • Women with menstruation at the time of admission
  • Pregnant women

Withdrawal criteria: presence of active gastrointestinal bleeding during the study inclusion period.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CBSD-experimental groupClosed-Blood Sampling Devicesblood collection with Closed-Blood Sampling System (CBSD)
Waste discard volume, control groupWaste discard volumeBlood collection without CBSD, usual practice, need to waste discard volume
Primary Outcome Measures
NameTimeMethod
Units of red blood cells transfusionEvery day during the ICU stay and up to a maximum of 21 days after randomization (day 0)

Number of red blood cells (RBC) units administered in both study groups

Secondary Outcome Measures
NameTimeMethod
Number and type of adverse eventsEvery day during the stay and up to a maximum of 21 days after randomization (day 0):

Arterial catheter-related adverse events in both groups (infection and/or catheter obstruction; lose of arterial pressure monitoring)

Volume of blood drawnEvery day during ICU stay and up to a maximum of 21 days after randomization (day 0).

Volume of blood drawn in mL for laboratory testing in both study groups

Levels of hemoglobine and hematocritEvery day during ICU stay and up to a maximum of 21 days after randomization (day 0).

Hemoglobin (Hb) in g/dL and hematocrit (%) in both study groups

© Copyright 2025. All Rights Reserved by MedPath